Skip to Content

Elekta AB Class B EKTA B Stock Quote

| Rating as of

Morningstar‘s Stock Analysis EKTA B

Valuation
Currency in SEK
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Elekta's North American Business Continues To Struggle

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We are maintaining our fair value estimate of SEK 127 for wide-moat Elekta following the release of first-quarter results. North America continues to disappoint, with order growth, while affected by difficult comparisons, still below our expectations. On the margin, the company struggles with ongoing inflationary and supply constraint pressures, and announced another restructuring program to reduce its cost structure. We continue to view shares as undervalued.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics EKTA B

Company Profile EKTA B

Business Description

Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company's installed base of more than 5,000 linear accelerators, GammaKnife and Unity platforms, and software is used in more than 6,000 hospitals globally. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and Asia-Pacific contributing the remainder.

Contact
Kungstensgatan 18, Box 7593
Stockholm, SE-103 93, Sweden
T +46 858725400
Industry Medical Instruments & Supplies
Most Recent Earnings Jul 31, 2022
Fiscal Year End Apr 30, 2023
Employees 4,723